依诺妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | B7-H3 |
| 臨床資料 | |
| 其他名稱 | MGA271 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1353485-38-7 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6474H9990N1726O2030S42 |
| 摩尔质量 | 145,829.71 g·mol−1 |
依诺妥珠单抗（INN：Enoblituzumab；开发代号：MGA271）是一种单克隆抗体，设计用于治疗癌症。[1]该药物是一种人源化IgG1κ单克隆抗体，可识别人类B7-H3（免疫调节剂B7家族的成员）。[2]
该药物由MacroGenics公司开发。[3]
参考资料
[编辑]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
- ^ Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B.; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for Immunotherapy of Cancer. 2022-04, 10 (4) [2024-03-12]. ISSN 2051-1426. PMC 9006844
. PMID 35414591. doi:10.1136/jitc-2021-004424. （原始内容存档于2024-06-16）.
- ^ Enoblituzumab (anti-B7-H3) – MacroGenics. macrogenics.com. [2024-03-12]. （原始内容存档于2024-03-12）.
